» Articles » PMID: 37752299

CT-based Body Composition in Diffuse Large B Cell Lymphoma Patients: Changes After Treatment and Association with Survival

Overview
Journal Radiol Med
Specialty Radiology
Date 2023 Sep 26
PMID 37752299
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Primary purpose was to assess changes of bone mineral density (BMD) in diffuse large B cell lymphoma (DLBCL) patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone R-CHOP (like) chemotherapy regimen. Secondary purposes were to assess other body composition features changes and to assess the association of pre-therapy values and their changes over time with survival.

Material And Methods: Patients selected underwent R-CHOP(like) regimen for DLBCL, and underwent PET-CT before and after treatment. Main clinical data collected included body mass index, date of last follow-up, date of progression, and date of death. From the low-dose CT images, BMD was assessed at the L1 level; the other body composition values, including muscle and fat distribution, were assessed at the L3 level by using a dedicated software. Descriptive statistics were reported as median and interquartile range, or frequencies and percentages. Statistical comparisons of body composition variables between pre- and post-treatment assessments were performed using the Wilcoxon matched pairs signed rank test. Non-normal distribution of variables was tested with the Shapiro-Wilk test. For qualitative variables, the Fisher exact test was used. Log rank test was used to compare survival between different subgroups of the study population defined by specific body composition cutoffs. The significance level was set at p < 0.05.

Results: Eighty-two patients were included. The mean follow-up was 37.5 ± 21.4 months. A significant difference was found in mean BMD before and after R-CHOP(like) treatment (p < 0.0001). The same trend was observed for mean skeletal muscle area (SMA) (p = 0.004) and mean skeletal muscle index (SMI) (p = 0.006). No significant association was demonstrated between body composition variables, PFS and OS.

Conclusion: R-CHOP(like) treatment in DLBCL patients was associated with significant reduction of BMD, SMA and SMI.

Citing Articles

Body composition quantified by CT: chemotherapy toxicity and prognosis in patients with diffuse large B-cell lymphoma.

An Y, Zhao W, Zuo L, Fan J, Chen Z, Jin X Abdom Radiol (NY). 2024; 50(3):1392-1402.

PMID: 39400587 DOI: 10.1007/s00261-024-04608-x.


Scientific Status Quo of Small Renal Lesions: Diagnostic Assessment and Radiomics.

Trovato P, Simonetti I, Morrone A, Fusco R, Setola S, Giacobbe G J Clin Med. 2024; 13(2).

PMID: 38256682 PMC: 10816509. DOI: 10.3390/jcm13020547.


Machine Learning and Radiomics Analysis for Tumor Budding Prediction in Colorectal Liver Metastases Magnetic Resonance Imaging Assessment.

Granata V, Fusco R, Brunese M, Ferrara G, Tatangelo F, Ottaiano A Diagnostics (Basel). 2024; 14(2).

PMID: 38248029 PMC: 10814152. DOI: 10.3390/diagnostics14020152.

References
1.
Armitage J, Gascoyne R, Lunning M, Cavalli F . Non-Hodgkin lymphoma. Lancet. 2017; 390(10091):298-310. DOI: 10.1016/S0140-6736(16)32407-2. View

2.
Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R . CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346(4):235-42. DOI: 10.1056/NEJMoa011795. View

3.
Svendsen P, Shekhrajka N, Nielsen K, Vestergaard P, Poulsen M, Vistisen A . R-CHOP(-like) treatment of diffuse large B-cell lymphoma significantly reduces CT-assessed vertebral bone density: a single center study of 111 patients. Leuk Lymphoma. 2016; 58(5):1105-1113. DOI: 10.1080/10428194.2016.1233543. View

4.
Ghielmini M, Vitolo U, Kimby E, Montoto S, Walewski J, Pfreundschuh M . ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Ann Oncol. 2012; 24(3):561-76. PMC: 6267877. DOI: 10.1093/annonc/mds517. View

5.
Zelenetz A, Gordon L, Chang J, Christian B, Abramson J, Advani R . NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021. J Natl Compr Canc Netw. 2021; 19(11):1218-1230. DOI: 10.6004/jnccn.2021.0054. View